$NSPX .0041? SEE WHAT DOCTORS ARE SAYING ABOUT ITS DRUG. SHOULD BE NO LESS THAN 10 CENTS DO U TRADE TO MAKE MONEY??!!
$NSPX 0041?! SERIOUSLY?!https://t.co/1PKOV8DPxx??? ;
LIKE HOW CAN PEOPLE LOOK THIS GIFT HORSE in the mouth like this???!! NSME AN OTC STOCK YOU KNOW trading at 0046 on the ask with only 150 million A/S. Now add that it's a pharmaceutical. NAME A PHARMACEUTICAL OTC STOCK with 150 million O/S trading less than 2 cents anywhere. AM I THE ONLY TRADER WHO DOES A COMPARATIVE MARKET ANALYSIS OF stocks???!!
Some say it went dark. Yes NSPX went dark after they purchased Lewis and Clark Pharmaceuticals A PRIVATE cancer biotech company with state of the art labs. Yes they went dark and silent but DID YOU SEE THE MASSIVE NEWS they silently released LESS THAN 3 MONTHS AGO???!! DID YOU???!
$NSPX eligible $12 MILLION from Transaction. Not 12 cents, 12 dollars, TWELVE MILLION DOLLARS!!!! Like this is nuts https://t.co/2iNhYy7KfE ;
LOOK AT NSPX BREAKTHROUGH DRUG THAT COULD REPLACE CHEMOTHERAPY. This was on the NEWS. Cancer research/cures dont happen over night and MISPARGARIN HAVE ALREADY CURED PATIENTS that everything else failed. .0046????! What???!! LOOK. https://youtu.be/fIgp4n3Itzo ;
NSPX I don't understand traders but makes no difference to me 150 million A/S for a pharmaceutical??????Even if it wasn't a pharmaceutical it would be DELICIOUS but as a pharmaceutical I multiply everything times 4. Pharmaceuticals always run WAYYYYYYYYYYYYYYYYY above their value. You have big board stocks trading in the $50+ range that haven't even reached phase 2 of clinical trials lol (true story). This is one of the rare cases when a pharmaceutical is EXTREMELY BELOW its intrinsic value. I MEAN THESE GUYS HAVE CANCER PATENTS and a drug that the medical community calls the cancer grenade and it's at 0046????!! No way, is this a dream or real life? Both in big boards and otc. Its crazy.
$GNSZ's Ph 2 mipsagargin data for #GBM showed clinical benefit in a subset of #glioblastoma patients. https://t.co/9bzvYKM0HA #SNO15 ;
Santosh Kesari, MD, PhD https://www.curetoday.com/articles/above-and-beyond-a-celebration-of-heroes-of-glioblastoma ;
; https://xconomy.com/texas/2016/02/03/pursuing-partner-genspera-tests-toxin-based-drug-in-brain-cancer/ ;
; https://www.pacificneuroscienceinstitute.org/people/kesari/https://abc7.com/health/doctor-improves-cancer-teens-health-with-game-changing-approach/1175310/ ;
$GNSZ combines powerful insights and rigorous scientific methods to create new treatment options for patients. https://t.co/oAwCWxky1HLearn more about
mipsagargin's unique mechanism of action that helps destroy #tumors. $GNSZ" rel="nofollow" target="_blank">https://t.co/NbEj6pHSdp $GNSZ #cancer
Patented technology platform has the potential to target different #cancers. Click to learn more: https://t.co/aIiLNdfgm3https://www.google.com/search?source=hp&ei=E-D7W4jHOsS-ggeM_pL4Cw&q=thapsigargin&oq=thapsi&gs_l=mobile-gws-wiz-hp.1.0.0l2j46i10j0j46i10.2095.4643..7756...1.0..0.346.1347.0j2j3j1......0....1.......5..46j35i39j46i39j0i131j46i131.fN_PcqrV8QM ;
Our lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. FDA in 2013 for evaluation in patients with hepatocellular carcinoma.
Devalingam Mahalingam, M.D., from Cancer Therapy & Research Center, describes the results of a Phase II study of GenSpera’s mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC), presented at ASCO GI 2015 on January 16, 2015. The Phase II results demonstrated that mipsagargin appears to be effective and well-tolerated by HCC patients. https://m.facebook.com/story.php?story_fbid=849502461751662&id=186857748016140 ;
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX